Identification of a Dantrolene-binding Sequence on the Skeletal Muscle Ryanodine Receptor*

Received for publication, June 3, 2002, and in revised form, July 10, 2002
Published, JBC Papers in Press, July 11, 2002, DOI 10.1074/jbc.M205487200

Kalanethee Paul-Pletzer,a Takeshi Yamamoto,b Manjunatha B. Bhat,a Jianjie Ma,d Noriaki Ikemoto,a,ab Leslie S. Jimenez,a Hiromi Morimoto,a Philip G. Williams,a,h and Jerome Parnessa,b,d,j,h

From the Departments of aAnesthesia, bPharmacology, cPediatrics, and dPhysiology and Biophysics, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, the eBoston Biomedical Research Institute, Watertown, Massachusetts 02472, the fDepartment of Neurology, Harvard Medical School, Boston, Massachusetts 02115, the gCenter for Anesthesiology Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, the hDepartment of Chemistry, Rutgers University, Piscataway, New Jersey 08854, the iNational Tritium Labelling Facility, E. O. Lawrence Berkeley Laboratory, Berkeley, California 94720, and the jDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California 94143

Dantrolene is a drug that suppresses intracellular Ca2+ release from sarcoplasmic reticulum (SR) in skeletal muscle and is used as a therapeutic agent in individuals susceptible to malignant hyperthermia. Although its precise mechanism of action has not been elucidated, we have identified the N-terminal region (amino acids 1–1400) of the skeletal muscle isoform of the ryanodine receptor (RyR1), the primary Ca2+ release channel in SR, as a molecular target for dantrolene using the photoaffinity analog [3H]azidodantrolene. Here, we demonstrate that heterologously expressed RyR1 retains its capacity to be specifically labeled with [3H]azidodantrolene, indicating that muscle specific factors are not required for this ligand-receptor interaction. Synthetic domain peptides of RyR1 previously shown to affect RyR1 function in vitro and in vivo were exploited as potential drug binding site mimics and used in photoaffinity labeling experiments. Only DP1 and DP1–2s, peptides containing the amino acid sequence corresponding to RyR1 residues 590–609, were specifically labeled by [3H]azidodantrolene. A monoclonal anti-RyR1 antibody that recognizes RyR1 and its 1400-amino acid N-terminal fragment recognizes DP1 and DP1–2s in both Western blots and immunoprecipitation assays and specifically inhibits [3H]azidodantrolene photolabeling of RyR1 and its N-terminal fragment in SR. Our results indicate that synthetic domain peptides can mimic a native, ligand-binding conformation in vitro and that the dantrolene-binding site and the epitope for the monoclonal antibody on RyR1 are equivalent and composed of amino acids 590–609.

Dantrolene is a hydantoin derivative used to treat malignant hyperthermia (MH), a rare, pharmacogenetic disorder of skeletal muscle characterized by uncontrolled Ca2+ release from sarcoplasmic reticulum (SR) stores in response to volatile anesthetics. Triggering of MH results in hypercontracture, hyperthermia, and eventually death. Therapeutics with dantrolene results from its effective suppression of skeletal muscle SR Ca2+ release, presumably by modulating the activity of the ryanodine receptor (RyR1), the primary Ca2+ release channel in skeletal muscle via that Ca2+ stored in the SR is released into the myoplasm to initiate muscle contraction in response to membrane depolarization (1). The genetic defect that causes MH in humans has been linked to point mutations in RyR1 in about 90% of patients. To date, some 26 MH-linked mutations in RyR1 have been identified: 9 in the extreme N-terminal region, 16 in the central region, and 1 in the extreme C-terminal region (2–7). Interestingly, a single amino acid deletion, rather than mutation, in the central region of RyR1 (Glu2347) has also been found to be associated with MH susceptibility (8).

Whether dantrolene suppression of Ca2+ release occurs via direct interaction with RyR1 is not entirely clear. Some have found evidence suggesting that RyR1 is not the target (9, 10), and others have found evidence that it is (1, 11, 12). Given the controversy as to the mechanism and, hence, the targets of dantrolene action, we have embarked on a project to directly identify the molecular target(s) of dantrolene by photoaffinity labeling. Knowing the target(s) of dantrolene binding would allow genetic and physiological manipulation of these molecular entities to not only elucidate the mechanism of action of this drug but also provide insights into the in vivo mechanisms controlling the RyR1 Ca2+ release channel in skeletal muscle excitation-contraction coupling and the pathophysiology of MH.

Recently, we have demonstrated that [3H]azidodantrolene, a pharmacologically active, photoaffinity analog of dantrolene, specifically labels the N-terminal, 1400-amino acid residue fragment of RyR1 cleaved by n-calpain, a tissue-specific isoform of this Ca2+- and thiol-activated protease (13). Several studies have demonstrated that this portion of the RyR plays a

1 The abbreviations used are: MH, malignant hyperthermia; AMP-PCP, β-y-methyleneadenosine 5′-triphosphate; CHO, Chinese hamster ovary; DHPR, dihydropyridine receptor; DP, domain peptide; mAb, monoclonal antibody; PIPES, piperazine-N,N′-bis(2-ethanesulfonic acid); PVDF, polyvinyl difluoride; RyR, ryanodine receptor; SCR, scrambled peptide; SR, sarcoplasmic reticulum.

* This work was supported by NIAMS, National Institutes of Health Grant 5 R01 AR45593 and clinical funds from the Department of Anesthesiology, UMDNJ-Robert Wood Johnson Medical School (to J. P.); National Science Foundation Grant CHE-9502149 and grants from the Petroleum Research Fund and the Charles and Johanna Busch Memorial Fund to L. S. J.; NIAMS, National Institutes of Health Grant AR-16922 (to N. I.); NCRR, National Institutes of Health Program Fund (to L. S. J.); NIAMS, National Institutes of Health Grant R01 AG-15556 (to J. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Anesthesiology, UMDNJ-Robert Wood Johnson Medical School, Staged Research Annex II, Rm. 117, 661 Hoes Ln., Piscataway, NJ 08854. Tel.: 732-235-4824; Fax: 732-235-4489; E-mail: parness@umdnj.edu.

This paper is available on line at http://www.jbc.org
significant role in the regulation of channel function (14–18). Additionally, the nine, N-terminal mutations in RyR1 linked to MH alluded to above are localized within this region of the channel.

The DHPR and RyR1 are intimate physiological partners during skeletal muscle excitation-contraction coupling. The evidence indicates that the DHPR is the voltage sensor in the T-tubule membrane that upon sensing depolarization undergoes a conformational change associated with intramolecular charge movement. This is believed to result in the movement of the intracellular loop between transmembrane domains II and III (II–III loop) of the DHPR α-1 subunit, which physically contacts the RyR1, inducing its opening and resultant Ca$^{2+}$ release from the SR (for reviews see Refs. 19 and 20). Previous studies have demonstrated the experimental utility of using synthetic domain peptides derived from the DHPR and RyR1 to define physiologically significant domains within the parent protein. In particular, peptides A and C of the DHPR II–III loop and domain peptides DP1 and DP4 of the RyR1 have been shown to be active in in vitro studies of excitation-contraction coupling (21–24). Interestingly, DP1 and DP4 are from the N-terminal and central regions of the RyR1 that are “hot spots” for mutations conferring sensitivity to MH and/or the rare MH alluded to above are localized within this region of the channel. Additionally, the nine, N-terminal mutations in RyR1 linked to MH (14–18) might reasonably attempt to express a region of the N-terminal portion of the channel that would retain its ability to bind dantrolene and assist us in localization of the drug-binding site.

In the present study, we demonstrate specific $[^3H]$azidodantrolene photolabeling of two domain peptides containing the core sequence corresponding to amino acid residues 590–609 on RyR1-DP1 (amino acids 590–609) and DP1–2s, an elongated version of the skeletal sequence present in DP1 (590–628). A monoclonal anti-RyR1 antibody raised against rabbit terminal cisternae (25) that recognizes both the intact rabbit RyR1 and the 172 kDa, n-calpain-cleaved, N-terminal fragment of this channel (13), also recognizes these synthetic RyR1 peptides. This antibody specifically inhibited $[^3H]$azidodantrolene photolabeling of RyR1 in SR in a concentration-dependent manner. These results indicate, therefore, that the dantrolene-binding site on RyR1 is comprised of amino acids 590–509.

### EXPERIMENTAL PROCEDURES

**Materials**—Dantrolene sodium·3·5H$_2$O and azumolene sodium·2H$_2$O were generous gifts of Proctor & Gamble (Norwich, NY). Polyclonal sheep anti-rabbit RyR1, monoclonal mouse (mAb) anti-rabbit RyR1 XA7 (mAb), and polyclonal rabbit anti-rabbit RyR1 C-terminal (raised against a synthetic C-terminal RyR1 peptide corresponding to amino acids 5023–5037) antibodies were generous gifts of Dr. K. P. Campbell (University of Iowa, Iowa City, IA). Rabbit fast twitch skeletal muscle was supplied by Dr. H. Weiss (UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ).

$[^3H]$Azidodantrolene Synthesis—$[^3H]$Azidodantrolene was synthesized, purified, and characterized exactly as described (26), and the specific activity was determined to be 28 Ci/mmol.

Peptide Synthesis—Rabbit RyR1 domain peptides (DP1, DP1–2s, DP4, DP3, and DP7), DP1 scrambled peptide SCR1, and rabbit skeletal muscle DHPR α-s1 subunit peptides (Pepα and PepC) were synthesized on an Applied Biosystems model 431 A synthesizer and purified by reversed-phase high performance liquid chromatography, as described (21, 27). DP1 scrambled peptide SCR4 was synthesized by Biosynthesis Inc. (Lewisville, TX). Scrambled DP1 sequences were generated by computer program, and SCR1 and SCR4 sequences were picked for subsequent synthesis.

Cloning and Expression of RyR1 in CHO Cells—The entire cDNA of RyR1 was cloned into the eukaryotic expression vector pRRS11 under the control of the SV40 promoter. Plasmid pRRS11 was introduced into CHO cells using the LipofectAMINE-mediated gene transfection method, as described previously (28, 29). Stable clones of CHO cells permanently transfected with RyR1 were selected using G418 (30, 31).

**Membrane Preparation**—Crude SR vesicles were prepared from rabbit fast twitch skeletal muscle in the presence of protease inhibitors (200 μg phenylmethylsulfonyl fluoride, 0.3 μM aprotonin, 10 μg/ml soybean trypsin inhibitor, and 2.5 μg pepstatin A) as described in Ref. 32. Microsomal membranes from CHO cells were obtained by ultracentrifugation of cell lysates prepared after sonication of cultured cells, as described (30). Leupeptin was specifically omitted from buffers used in membrane preparation to specifically allow for n-calpain cleavage of RyR1 and subsequent identification of its 172-kDa, N-terminal fragment, if present (13, 33).

**Photolabeling with $[^3H]$Azidodantrolene—SR vesicles (100 μg) and CHO microsomal membranes (200 μg) were photolabeled with $[^3H]$Azidodantrolene (100–200 nM) in binding buffer (20 mM PIPES, pH 7, containing 0.5 mM AMP-PCP) in the absence (T, total binding) or presence (N, non-specific binding) of azumolene (150–300 μM), as described previously (13). For inhibition of photolabeling by mAb anti-RyR1, mouse ascites were added to the binding buffer at dilutions of 1:50, 1:25, and 1:10 in the presence of protease inhibitors (see “Membrane Preparation” above) with the addition of 1 mM leupeptin. Synthetic peptides (12.5 μM) were photolabeled with 50–100 nM $[^3H]$Azidodantrolene in binding buffer containing 10 μg of bovine serum albumin in the absence of AMP-PCP. Following photolabeling, the samples were resolved by SDS-PAGE (5% acrylamide for SR samples and 4% for synthetic peptides (34)).

**Autoradiography and Western Blot Analysis**—For autoradiography and Western blot analyses, the SDS-PAGE resolved proteins were electroblotted onto PVDF membranes (Sequii-Blot; Bio-Rad) (28). Autoradiography was performed as described (13). For Western blots, the membranes were probed with primary antibody at appropriate dilution/concentration (polyclonal anti-RyR1, 1:5000; mAb, 1:1000), followed by alkaline phosphatase-conjugated secondary antibody. Immunoreactive bands were visualized with 5-bromo-4-chloro-3-indolyl phosphate/p-nitro blue tetrazolium using standard procedures.

### RESULTS

$[^3H]$Azidodantrolene Photolabels Expressed RyR1 in CHO Cells—Of the 5037 amino acids that constitute the RyR1 sequence, we have shown that a dantrolene-binding site resides between amino acids 1 and 1400 of the N-terminal region of the channel (13). In an attempt to devise a molecular biological approach to define the amino acids that comprise the dantrolene-binding site, we first asked whether RyR1 is capable of specifically interacting with dantrolene in the absence of a muscle cell background. We reasoned that if it did, (a) this would corroborate our finding that the RyR1 is a pharmacological target of dantrolene and (b) we might reasonably attempt to express a region of the N-terminal portion of the channel that would retain its ability to bind dantrolene and assist us in localization of the drug-binding site.

We used recombinant RyR1, stably expressed in CHO cells, as a target for our photoaffinity labeling experiments. Microsomal membranes prepared from these cells, along with rabbit skeletal muscle SR vesicles as positive control, were photolabeled with $[^3H]$Azidodantrolene in the presence or absence of AMP-PCP and excess azumolene, as described under “Experimental Procedures”. As shown in Fig. 1A, specific photolabeling of a 565-kDa protein corresponding to the RyR1 monomer in SR vesicles in CHO microsomal membranes expressing RyR1. This photolabeling is dependent on the presence of AMP-PCP. This is identical to the requirements for photolabeling of RyR1 and its 172-kDa fragment in SR reported previously (13). The Western blot (Fig. 1B) of the same membrane used for autoradiography, probed with a polyclonal anti-RyR1 antibody, demonstrates equivalent protein loading in all the experimental lanes and confirms that the radiolabeled band in
Ref: Specific[^H]Azidodantrolene photolabeling of recombinant RyR1. SR vesicles (100 μg of protein) and CHO microsomes (200 μg of protein) expressing full-length rabbit RyR1 were photolabeled with[^H]Azidodantrolene in the absence (lanes T) or presence (lanes N) of azumolene and in the absence or presence of AMP-PCP. Following photolabeling, the proteins were fractionated by SDS-PAGE, electrophoresed onto PVDF membrane, and subjected to autoradiography. A, specific photolabeling of the 565-kDa RyR1 monomer was observed in SR and in CHO cells expressing full-length RyR1, only in the presence of AMP-PCP. No specific photolabeling was observed in mock-transfected control cells (Ctrl). The N-terminal, 172-kDa proteolytic fragment of RyR1 was photolabeled only in SR. The Western blot (B) of the same membrane used for autoradiography, probed with polyclonal anti-RyR1 antibody, reveals the presence of RyR1 proteins in all samples except in control samples. Note the lack of immunoreactive 172-kDa protein in the RyR1-transfected CHO cells.

CHO cell extracts are indeed RyR1. No specific photolabeling or anti-RyR1 immunoreactive bands were observed in membranes prepared from untransfected CHO cells. These results demonstrate that (a) dantrolene can bind to heterologously expressed RyR1 in the absence of other muscle-specific proteins and (b) this binding is pharmacologically specific and dependent on adenine nucleotide triphosphate, a known regulator of the channel protein.

Specific[^H]Azidodantrolene Photolabeling of Synthetic Domain Peptides of RyR1—To determine the amino acids on RyR1 that constitute the binding site for dantrolene, we attempted to specifically photolabel a heterologously expressed, green fluorescent protein-tagged, RyR1-N-terminal fragment containing amino acids 182-1608. This fragment did not label, presumably because of incorrect folding or processing (data not shown). We then turned to synthetic domain peptides of RyR1 as possible surrogate targets for the dantrolene-binding site. We synthesized four peptides with amino acid residues from within the N-terminal, 172-kDa proteolytic fragment of RyR1 (DP1, DP1–2s, and DP7), as well as peptides from the central region of RyR1 (DP3, and DP7), as well as peptides from the central region of RyR1 (DP4) and from the II–III loop of the DHPR-c subunit (PepA and PepC) (Fig. 2). These peptides were photoreacted with[^H]Azidodantrolene in the presence or the absence of excess azumolene, and the peptides were analyzed for specific photolabeling by autoradiography. The autoradiograph in Fig. 3A demonstrates specific photolabeling of DP1 (amino acid residues 590–609) and an elongated version of DP1, DP1–2s (amino acid residues 590–628). DP7 (amino acid residues 543–576) was nonspecifically labeled, whereas the other peptides were not labeled at all. The pharmacological specificity of[^H]Azidodantrolene labeling of DP1 was demonstrated by the ability of dantrolene and azumolene, but not the unrelated drug, atropine, to inhibit this interaction (Fig. 3B). In addition, scrambling of the DP1 sequence (Fig. 3D, SCR1 and SCR4) led only to nonspecific labeling of varying intensity (Fig. 3C). These results suggest that DP1 might represent an in vitro model of the dantrolene-binding site on RyR1.

A Monoclonal Anti-RyR1 Antibody Recognizes DP1—Our previous work has shown that an anti-RyR1 mAb immunoprecipitates[^H]Azidodantrolene-labeled RyR1 and its 172-kDa fragment from solubilized SR (13). Given the epitope specificity of monoclonal antibodies and that the epitope of this monoclonal seemed to be on the 172-kDa protein, we reasoned that it was possible that one of our domain peptides corresponding to sequences from the N-terminal region of RyR1 might interact with this antibody. If it did, it would demonstrate the feasibility of using synthetic peptides to mimic a protein epitope in this channel.

First, to confirm our earlier results described above, we demonstrated that only intact RyR1 and its 172-kDa N-terminal fragment were reactive with the monoclonal antibody by photolabeling duplicate SR samples with[^H]Azidodantrolene, electroblotting these onto PVDF membranes after SDS-PAGE, and probing one sample with mAb anti-RyR1 and the other with polyclonal anti-RyR1 antibody, reveals the presence of RyR1 proteins in all samples except in control samples. Note the lack of immunoreactive 172-kDa protein in the RyR1-transfected CHO cells.

Specific[^H]Azidodantrolene photolabeling of recombinant RyR1. SR vesicles (100 μg of protein) and CHO microsomes (200 μg of protein) expressing full-length rabbit RyR1 were photolabeled with[^H]Azidodantrolene in the absence (lanes T) or presence (lanes N) of azumolene and in the absence or presence of AMP-PCP. Following photolabeling, the proteins were fractionated by SDS-PAGE, electrophoresed onto PVDF membrane, and subjected to autoradiography. A, specific photolabeling of the 565-kDa RyR1 monomer was obtained in SR and in CHO cells expressing full-length RyR1, only in the presence of AMP-PCP. No specific photolabeling was obtained in mock-transfected control cells (Ctrl). The N-terminal, 172-kDa proteolytic fragment of RyR1 was photolabeled only in SR. The Western blot (B) of the same membrane used for autoradiography, probed with polyclonal anti-RyR1 antibody, reveals the presence of RyR1 proteins in all samples except in control samples. Note the lack of immunoreactive 172-kDa protein in the RyR1-transfected CHO cells.

**FIG. 1.** Specific[^H]Azidodantrolene photolabeling of recombinant RyR1. SR vesicles (100 μg of protein) and CHO microsomes (200 μg of protein) expressing full-length rabbit RyR1 were photolabeled with[^H]Azidodantrolene in the absence (lanes T) or presence (lanes N) of azumolene and in the absence or presence of AMP-PCP. Following photolabeling, the proteins were fractionated by SDS-PAGE, electrophoresed onto PVDF membrane, and subjected to autoradiography. A, specific photolabeling of the 565-kDa RyR1 monomer was obtained in SR and in CHO cells expressing full-length RyR1, only in the presence of AMP-PCP. No specific photolabeling was obtained in mock-transfected control cells (Ctrl). The N-terminal, 172-kDa proteolytic fragment of RyR1 was photolabeled only in SR. The Western blot (B) of the same membrane used for autoradiography, probed with polyclonal anti-RyR1 antibody, reveals the presence of RyR1 proteins in all samples except in control samples. Note the lack of immunoreactive 172-kDa protein in the RyR1-transfected CHO cells.
Identification of a Dantrolene-binding Sequence on RyR1

**Fig. 2.** Sequences of synthetic RyR1 and DHPR α1 subunit domain peptides. Various domain peptides of RyR1 and the skeletal muscle, α1 subunit of the DHPR were synthesized to test in our in vitro photoaffinity labeling and antibody immunoreactivity assays: DP3, DP1, DP1–2s, and DP7 from the N-terminal region of RyR1, DP4 from its central portion, and PepA and PepC from the II–III loop region of the α1 subunit of skeletal muscle DHPR.

<table>
<thead>
<tr>
<th>PEPTIDE</th>
<th>AMINO ACID #</th>
<th>SEQUENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>RyR1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DP3</td>
<td>324-51</td>
<td>DTAPKRDVEGMPFEIKYGERSLFCQHV</td>
</tr>
<tr>
<td>DP7</td>
<td>543-76</td>
<td>NLDWYVSKLRLEASGGGILEVLVCLIESPEVLN</td>
</tr>
<tr>
<td>DP4</td>
<td>2442-77</td>
<td>LIGAGKKAIIRILRSLYFPDDLVDLSIDPOQIP</td>
</tr>
<tr>
<td>DP1</td>
<td>590-609</td>
<td>LDKHRMNHDVCSLSCVC</td>
</tr>
<tr>
<td>DP1-2S</td>
<td>590-628</td>
<td>LDKHRMNHDVCSLSCVCNGVAVRSQDLITENLPG</td>
</tr>
<tr>
<td>DHPR II–III LOOP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PeptA</td>
<td>671-690</td>
<td>TSKQAKKEERKRMKMSL</td>
</tr>
<tr>
<td>PeptC</td>
<td>724-760</td>
<td>EFESNVMEKDPFYPADFFGDEDDEFEIPVSPRE</td>
</tr>
</tbody>
</table>

**DISCUSSION**

It is our hypothesis that understanding the molecular mechanism of action of dantrolene will lead to a better understanding of the physiology of MH, the mechanism of excitation-contraction coupling, and the regulation of intracellular Ca$^{2+}$/H$^+$ release from SR. A prerequisite for elucidating molecular mechanisms requires the identification of molecular target(s). The biochemical identification of amino acids involved in drug binding allows for the design of mutational experiments to test their functional significance in drug action. Here, we have amassed evidence that the amino acid sequence of the dantrolene-binding site on RyR1 corresponds to amino acids 590–609, corresponding to the synthetic domain peptide DP1. The most compelling evidence for the DP1 sequence being the dantrolene-binding sequence in RyR1 comes from our experiments with the monoclonal antibody, mAb anti-RyR1. In 1987, Campbell et al. (25) produced an IgM anti-RyR1 mAb, clone XA7, of uncharacterized epitope, that specifically immunoprecipitates $[^3]$H]ryanodine-bound RyR1. Our present studies demonstrate that this antibody recognizes its epitope not only on the RyR1 monomer and its 172-kDa N-terminal, calpain cleavage fragment but also on the synthetic peptides, DP1 and DP1–2s, containing the core RyR1 sequence 590–609. Most
FIG. 6. Inhibition of [3H]azidodantrolene photolabeling of RyR1 by mAb anti-RyR1. A, SR vesicles were photolabeled in the absence (lanes T) or in the presence (lanes N) of azumolene and in the absence or presence of increasing dilutions of mAb ascites in binding buffer (1:10, 1:25, and 1:50). Photolabeling in the presence of an equivalent concentration of IgM as total protein in the 1:10 diluted mouse ascites was used as a negative control. B, the blot used for autoradiography was probed with polyclonal anti-RyR1 antibody. C, quantification of radiolabeled bands as a function of mAb dilution in A using ImageQuant for Windows NT™ software.

Identification of a Dantrolene-binding Sequence on RyR1

significantly, this antibody specifically inhibits [3H]azidodantrolene photolabeling of RyR1 and its 172-kDa fragment in SR in a concentration-dependent manner. This result is consistent with our earlier experiments demonstrating the absence of a dantrolene-binding site on RyR1 C-terminal to the n-calpain cleavage site between amino acids 1400–1401 (13). The fact that we were able to demonstrate virtually complete inhibition of [3H]azidodantrolene photolabeling of the 172-kDa fragment with a monoclonal antibody is a strong argument that the epitope defined by this antibody, amino acids 590–609, represents the only dantrolene-binding site on RyR1. The relatively high concentrations (1:50 dilution) of mouse ascites required to bring about inhibition of specific photolabeling is likely due to the low antigen affinities of IgM antibodies, which are part of the early immune response of the body, relative to mature IgG antibodies (29). These data also strengthen the experimental evidence that, in vitro, synthetic domain peptides are capable of assuming the native conformation(s) of domains present in the parent protein, RyR1 in this case (35–37).

Previous studies have already shown that heterologously expressed RyR1 in CHO cells forms functional channels (38) and allowed us to address the question of whether dantrolene binding to RyR1 requires the presence of muscle-specific factors in heterologously expressed channels. Here, we have demonstrated that RyR1 can interact directly with dantrolene in the absence of a muscle-specific milieu. That this interaction is modulated by AMP-PCP, as it is in SR (13), substantiates our assertion that this drug-channel interaction is pharmaco logically relevant. It further indicates that this nucleotide analog affects RyR1 directly in enhancing the ability of this channel to bind dantrolene. Specific photolabeling of the synthetic peptide, DP1, on the other hand, should be independent of all specific regulators of RyR1 activity, because none of the putative nucleotide or protein regulatory sites on RyR1 would be expected to be associated with this 20-amino acid peptide. Indeed, our data demonstrate that [3H]azidodantrolene photolabeling of the two DP1 sequence-containing peptides is independent of AMP-PCP (data not shown). Although we have presented strong evidence that the dantrolene-binding site on RyR1 is modulated by this nucleotide analog, it is not yet clear how ATP might modulate the activity of this drug in vivo.

A recent, detailed examination of the possible physiological site(s) of dantrolene action in skeletal muscle has shown that dantrolene suppresses but never completely eliminates intracellular Ca²⁺ release in whole and skinned muscle fibers or from SR vesicles but has no effect on purified RyR1 incorporated into lipid bilayers (10). These results led those authors to conclude that RyR1 is not likely the site of action of dantrolene. This result is in stark contrast to our results above and those of Nelson and colleagues (11). Possible unifying explanations of these disparate results are likely to be methodologic and could include the following: (a) the dantrolene-binding site on RyR1 is uniquely sensitive to modification during the purification process rendering it dantrolene insensitive under certain, as yet undefined conditions or (b) the physiological effects of dantrolene binding to RyR1 requires the interaction of other RyR1 interacting factors that might be removed during purification or whose interactions are not modeled well in the artificial lipid bilayer.

Comparing the DP1 sequence in RyR1 with the other rabbit isoforms reveals that there is an identical sequence in RyR2 (601–619) and a nearly identical one in RyR3 (577–597), with a conservative amino acid substitution (Val to Leu) at position 596 (39). If this sequence is the dantrolene-binding site, all three should be sensitive to this drug. Yet, existing evidence indicates that only the RyR1 and RyR3 isoforms are sensitive to dantrolene. We have shown by [3H]azidodantrolene photolabeling of SR vesicles prepared from skeletal or cardiac muscle that only RyR1 is a good target for dantrolene, not RyR2 (13). Similarly, other laboratories have shown that dantrolene can inhibit [3H]ryanodine binding to RyR1 and RyR3 but not RyR2 (1, 12). If the DP1 sequence is the dantrolene-binding site, why is the RyR2 isoform insensitive to this drug when it contains the identical sequence? The most likely explanation at our present state of knowledge is that the domain-domain interactions within RyR2 constrain the conformation around this sequence so that dantrolene is no longer able to bind with high affinity to this site. Other possible explanations include RyR2-associated proteins or post-translational modifications of the channel that block access to the site. The underlying reasons for the differences in dantrolene sensitivity of RyR2 relative to RyR1 are under active investigation in our laboratory.

As noted above, the DP1 sequence of RyR1 is nearly identical in RyR3. Whether this isoform is responsive to dantrolene in the organs in which this isoform is expressed remains to be clarified. Early studies indicated that dantrolene has no effect on smooth muscle contractility (41), although more recent studies contradict that (42). Indeed, the latter studies are strongly
Identification of a Dantrolene-binding Sequence on RyR1

34923

supported by the demonstration that heterologously expressed RyR3 has been shown to be responsive to dantrolene (12). If RyR3 is indeed a target of dantrolene, then this last result might explain the various effects of dantrolene seen in non-muscle tissues that express RyR3, *i.e.* neuronal and immune cells (43, 44).

Recently, Ikemoto and co-workers (21, 27) demonstrated that DP1 added to SR vesicles activates RyR1, as measured by enhanced [3H]ryanodine binding. These authors have postulated that DP1 may be assuming the native conformation of the identical sequence in the channel (domain x), thereby competing with this domain for its interacting or "mating" domain (domain y) on RyR1, resulting in "unzipping" of the native RyR1 domain x-domain y interactions (24, 40, 45). If, under normal resting conditions, domain x-domain y interactions would keep the channel in a closed state, unzipping these interactions should result in activation of the channel. It follows that the insinuation of DP1 into the normal domain x position, mating or unzipping to domain y of RyR1, would result in loss of the conformational constraints imparted by these zipped domains and lead to channel opening. If the above is true, then the most parsimonious explanation of the results to date is that dantrolene inhibits RyR1-mediated Ca2+ release by stabilizing the interdomain x-y interactions. Moreover, dantrolene stabilization of these interdomain interactions may even result in stabilization of other protein domain-domain interactions, either within RyR1 or with another interacting protein(s) or both, thus reducing the likelihood of channel openings and inhibiting Ca2+ release. Elucidation of the identity of the putative interacting domain(s) and modeling of the dantrolene-binding site in the three channel isoforms would greatly contribute to our understanding of the regulation of RyR channel function.

Acknowledgments—We regret the untimely closing of the National Tritium Labelling Facility as a national resource and acknowledge the formidable contributions of this resource to our research program in particular and national biomedical small molecule research programs in general.

REFERENCES


Downloaded from http://www.jbc.org/ by guest on October 10, 2017
Identification of a Dantrolene-binding Sequence on the Skeletal Muscle Ryanodine Receptor
Kalanethee Paul-Pletzer, Takeshi Yamamoto, Manjunatha B. Bhat, Jianjie Ma, Noriaki Ikemoto, Leslie S. Jimenez, Hiromi Morimoto, Philip G. Williams and Jerome Parness

doi: 10.1074/jbc.M205487200 originally published online July 11, 2002

Access the most updated version of this article at doi: 10.1074/jbc.M205487200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 45 references, 16 of which can be accessed free at http://www.jbc.org/content/277/38/34918.full.html#ref-list-1